


# Respiratory Syncytial Virus (RSV)

## Overview














RSV is a common respiratory virus that usually causes mild, cold-like symptoms.<sup>1</sup> Most people infected recover in a week or two, but RSV can be serious, especially for infants and older adults. RSV is responsible for 2.1 million outpatient visits, over 200,000 hospitalizations, and up to 13,000 deaths each year.<sup>2</sup> RSV is the most common cause of bronchiolitis and pneumonia in children younger than 1 year of age in the U.S. Almost all children will have had an RSV infection by the age of 2 years.<sup>3</sup> It is also a significant cause of respiratory illness in older adults.<sup>1</sup> Prior to 2020, RSV followed predictable seasonal patterns in the U.S. A typical RSV season ran between October and May, with the most cases in early February. However, because of restrictions on activity and behavior changes due to the COVID-19 pandemic, RSV has not been spreading in its usual pattern since 2020. We don't know when, or if, the predictable seasonal spreading of RSV will return.<sup>2</sup>

## About the Pathogen & Infection Control Measures

<b>Infectious Agent (Pathogen)<sup>4</sup></b>	<b>Agent Type:</b> Virus <b>Taxonomy:</b> <b>Family:</b> Pneumoviridae <b>Genus:</b> <i>Orthopneumovirus</i>	<b>Species:</b> <i>Human orthopneumovirus</i> <b>Subtypes:</b> A and B <b>Synonym(s):</b> RSV, Human respiratory syncytial virus (hRSV), Pneumovirus <sup>5</sup> <b>Characteristics:</b> Enveloped virus
<b>Infectious Characteristics Definitions:</b> <b>Incubation period</b> —the time from exposure to infection with symptoms. <b>Period of communicability</b> —time when a pathogen can be transmitted from one person to another.	<b>Risk factors for severe infection:<sup>6</sup></b>	<b>Age:</b> Infants and children younger than two years old and older adults, especially 65 years and older <b>Pre-existing conditions:</b> Weakened immune system, neuromuscular disorders, chronic heart disease, or lung disease
	<b>Incubation period:<sup>3</sup></b>	4–6 days
	<b>Period of communicability:<sup>7</sup></b>	3–8 days after symptom onset Up to 4 weeks in infants and those who are immunocompromised
	<b>Signs &amp; symptoms:<sup>3</sup></b>	<b>Symptoms appear in stages:</b> Runny nose, decreased appetite, coughing, sneezing, fever, wheezing In very young infants: irritability, decreased activity, and breathing difficulties
	<b>Duration of illness:<sup>3</sup></b>	Most RSV infections resolve on their own within a week or two
	<b>Severity of illness:<sup>3</sup></b>	Severity ranges from mild to more severe infections such as bronchiolitis and pneumonia
<b>Mode(s) of Transmission<sup>5</sup></b> How the Infection Spreads	Contact: Direct from person-person when an infected person coughs or sneezes and indirect from contaminated	
<b>Survival on Surfaces<sup>8</sup></b>	7–8 hours	
<b>Immunization/Prophylaxis/Treatment</b>	An RSV vaccine has been approved by the FDA for individuals 60 years of age and older and pregnant women to protect newborns. <sup>9</sup> An RSV vaccine for the general public, including infants and children, is not available at this time. There is a monoclonal antibody treatment administered monthly during the RSV season to high-risk infants. <sup>10</sup>	
<b>Infection Control Measures</b>	<b>General Measures For All Spaces</b> (commercial buildings, K–12 schools, healthcare): <sup>11</sup> Practice respiratory hygiene and cough etiquette (e.g., covering coughs and sneezes). Perform frequent hand hygiene. Stay home when ill. Encourage those who are sick to stay home and limit contact with others. Develop non-punitive sick leave policies	<b>Healthcare-Specific Measures:<sup>12</sup></b> <b>Isolation Precautions:</b> Contact + Standard Precautions for the duration of illness. Extend duration of contact precautions for immunocompromised patients due to prolonged shedding <b>PPE:</b> Gown and gloves. Mask according to Standard Precautions to prevent respiratory droplets from coming into contact with mucous membranes <b>Linen:</b> Per routine <b>Waste management:</b> per routine
<b>Cleaning &amp; Disinfection<sup>11</sup></b>	Standard cleaning & disinfection procedures, with increased frequency of high-touch surfaces that may be contaminated with the virus. Use EPA-registered disinfectants with an RSV claim.	

# Clorox Product Recommendations

The following CloroxPro cleaner-disinfectants can be used to effectively manage RSV on environmental surfaces and equipment.

Products for use against Respiratory Syncytial Virus (RSV)		EPA Reg. No.	RSV contact time
<b>Clorox Clorox EcoClean™ Disinfecting Cleaner and Refill</b> Item No. 60213 9/32 oz. Spray Item No. 60094 4/128 oz. Refill		67619-45	30 seconds
<b>CloroxPro® Clorox® Germicidal Bleach</b> Item No. 30966 3/121 fl. oz. Bottle		67619-32	5 minutes
<b>CloroxPro® Clean-Up® Disinfectant Cleaner with Bleach</b> Item No. 35417 9/32 fl. oz. Spray Item No. 35420 4/128 oz. Refill		67619-17	30 seconds
<b>CloroxPro® Clorox® Disinfecting Wipes</b> Item No. 15949 Fresh Scent Wipes, 6/75 ct. Item No. 15948 Lemon Scent Wipes, 6/75 ct. Item No. 31547 Fresh Scent Wipes, 1/700 ct. bucket Item No. 31428 Fresh Scent Wipes, 2/700 ct. refill		67619-31	15 seconds
<b>Clorox Commercial Solutions® Clorox® Disinfecting Spray</b> Item No. 38504 12/19 fl. oz. Aerosol Spray		67619-21	30 seconds
<b>Clorox Healthcare® Bleach Germicidal Wipes</b> Item No. 30577 6" x 5" Wipes Canister 6/150 ct. Item No. 35309 6.75" x 9" Wipes Canister 6/70 ct. Item No. 32621 6.75" x 9" Wipes Softpack 9/100 ct. Item No. 31424 6.75" x 9" Individual Wipes 6/50 ct. Item No. 30358 12" x 12" Wipes Bucket 2/110 ct. Item No. 30359 12" x 12" Wipes Bucket Refill 2/110 ct.		67619-12	1 minute
<b>Clorox Healthcare® VersaSure® Cleaner Disinfectant Wipes</b> 6.75" x 8" Multi-purpose Wipes, 6/85 ct., Item No. 31757 6" x 5" Multi-purpose Wipes, 6/150 ct., Item No. 31758 12" x 12" Terminal Wipes, 2/110 ct., Item No. 31759 12" x 12" Terminal Wipes Refill, 2/110 ct., Item No. 31761		56392-7	30 seconds
<b>Clorox Healthcare® Hydrogen Peroxide Cleaner Disinfectant Cleaner</b> Item No. 30828 9/32 fl. oz. Spray Item No. 30829 4/128 fl. oz. Refill		67619-24	30 seconds
<b>Clorox Healthcare® Hydrogen Peroxide Cleaner Disinfectant Wipes</b> Item No. 30824 6.75" x 9" Wipes Canister 6/95 ct. Item No. 30825 6.75" x 5.75" Wipes Canister 6/155 ct. Item No. 30826 12" x 11" Wipes Bucket 2/185 ct. Item No. 30827 12" x 11" Wipes Bucket Refill 2/185 ct.		67619-25	30 seconds
<b>Clorox Healthcare® Fuzion® Cleaner Disinfectant</b> Item No. 31478 9/32 fl. oz. Spray		67619-30	1 minute
<b>Clorox Healthcare® Spore<sup>10</sup> Defense® Cleaner Disinfectant</b> Item No. 32122 4/128 fl. oz. For Total 360 Item No. 32409 4/128 fl. oz. Bottle		67619-40	1 minute

## References:

1. CDC. Respiratory Syncytial Virus Infection (RSV). [Internet]. [cited 2023 May 24]. Available from <https://www.cdc.gov/rsv/index.html>.
2. CDC. RSV Trends and Surveillance. [Internet]. [cited 2023 May 24]. Available from <https://www.cdc.gov/rsv/research/us-surveillance.html>
3. CDC. RSV Symptoms. [Internet]. [cited 2023 May 24]. Available from <https://www.cdc.gov/rsv/about/symptoms.html>
4. WHO. Respiratory syncytial virus (RSV) disease [Internet]. [cited 2023 Jun 1]. Available from: <https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/respiratory-syncytial-virus-disease>
5. Government of Canada. Pathogen Safety Data Sheets: Infectious Substances – Respiratory syncytial virus [Internet]. [cited 2023 Jun 1]. Available from: <https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/respiratory-syncytial-virus.html>
6. CDC. People at high risk for severe RSV infection [Internet]. [cited 2023 May 24]. Available from: <https://www.cdc.gov/rsv/high-risk/index.html>
7. CDC. RSV Transmission. [Internet]. [cited 2022 Oct 27]. Available from <https://www.cdc.gov/rsv/about/transmission.html>
8. Wißmann, J. E., Kirchhoff, L., Brüggemann, Y., et al. (2021). Persistence of pathogens on inanimate surfaces: A narrative review. Microorganisms, 9(2), 343.
9. American Medical Association. COVID and RSV vaccines during pregnancy, new mpox vaccine data with Andrea Garcia, JD, MPH [Internet]. 2023 [cited 2023 Jun 1]. Available from: <https://www.ama-assn.org/delivering-care/public-health/covid-and-rsv-vaccines-during-pregnancy-new-mpox-vaccine-data-andrea>
10. SYNAGIS (palivizumab) for prevention of Severe RSV Disease [Internet]. [cited 2023 Jun 1]. Available from: <https://www.synagis.com/what-is-synagis.html>
11. CDC. RSV Prevention. [Internet]. [cited 2023 May 24]. Available from <https://www.cdc.gov/rsv/about/prevention.html>
12. CDC. Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings, Appendix A, 2007. [Internet]. [cited 2023 May 24]. Available from <https://www.cdc.gov/infectioncontrol/guidelines/isolation/appendix/type-duration-precautions>



For product resources and implementation tools, contact your Clorox sales representative or call 800-234-7700 Visit: [www.CloroxHealthcare.com](http://www.CloroxHealthcare.com)

© 2023 Clorox Professional Products Company, 1221 Broadway, Oakland, CA 94612.

NI-60911